Education
About Us
Working with TipRanks
Follow Us
Sera Prognostics (SERA)
NASDAQ:SERA
SERA Stock Chart & Stats
$2.29
$0.42(5.34%)
At close: 4:00 PM EST
$2.29
$0.42(5.34%)
Day’s Range― - ―
52-Week Range$1.37 - $4.39
Previous CloseN/A
Volume57.63K
Average Volume (3M)40.22K
Market Cap
$88.38M
Enterprise Value$84.53M
Total Cash (Recent Filing)$43.30M
Total Debt (Recent Filing)$2.45M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Mar 25, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding37,627,033
10 Day Avg. Volume55,279
30 Day Avg. Volume40,220
Financial Highlights & Ratios
PEG Ratio0.56
Price to Book (P/B)5.65
Price to Sales (P/S)3505.16
P/FCF Ratio-17.65
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue889.80
Enterprise Value/Gross Profit-1.43K
Enterprise Value/Ebitda-2.67
Forecast
1Y Price Target
$5.00Price Target Upside118.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.7
Revenue Forecast (FY)$1.08M
Bulls Say, Bears Say
Bulls Say
Clinical Outcomes EvidenceResults showing substantially fewer early preterm births in the screen-guided care arm provide persuasive evidence that PreTRM-guided care can improve neonatal outcomes and influence clinical practice.
Payer And Health-system PartnershipsActive outreach to payers, integrated health systems, and professional societies, together with an insurer collaboration, strengthens pathways for reimbursement and wider adoption of the PreTRM test.
Peer-reviewed PublicationPublication of the PRIME study in a peer-reviewed medical journal establishes clinical credibility for the PreTRM test and supports more substantive commercial discussions with payers and providers.
Bears Say
Limited Commercial ImpactPublication alone may not generate a material increase in test volumes, leaving revenue growth reliant on effective commercialization and payer coverage execution.
Physician Adoption BarriersPotential physician resistance and the need for additional clinical data could slow adoption rates and delay payer coverage decisions, impeding market penetration.
Single-product ConcentrationDependence on a single commercial test creates exposure if market uptake stalls or competitors emerge, since the pipeline beyond the initial offering remains unproven.
Sera Prognostics News
SERA FAQ
What was Sera Prognostics’s price range in the past 12 months?
Sera Prognostics lowest stock price was $1.37 and its highest was $4.39 in the past 12 months.
What is Sera Prognostics’s market cap?
Sera Prognostics’s market cap is $88.38M.
When is Sera Prognostics’s upcoming earnings report date?
Sera Prognostics’s upcoming earnings report date is Mar 25, 2026 which is in 23 days.
How were Sera Prognostics’s earnings last quarter?
Sera Prognostics released its earnings results on Nov 13, 2025. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.198 by $0.038.
Is Sera Prognostics overvalued?
According to Wall Street analysts Sera Prognostics’s price is currently Undervalued.
Does Sera Prognostics pay dividends?
Sera Prognostics does not currently pay dividends.
What is Sera Prognostics’s EPS estimate?
Sera Prognostics’s EPS estimate is -0.19.
How many shares outstanding does Sera Prognostics have?
Sera Prognostics has 37,627,033 shares outstanding.
What happened to Sera Prognostics’s price movement after its last earnings report?
Sera Prognostics reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.198. Following the earnings report the stock price went up 0.339%.
Which hedge fund is a major shareholder of Sera Prognostics?
Currently, no hedge funds are holding shares in SERA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sera Prognostics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (118.34% Upside)
$5.00 (118.34% Upside)
Blogger Sentiment
Neutral
SERA Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $222.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-58.89%
12-Months-Change
Fundamentals
Return on Equity
-47.69%
Trailing 12-Months
Asset Growth
36.87%
Trailing 12-Months
Company Description
Sera Prognostics
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
SERA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant strategic progress with Medicaid pilot programs and leadership appointments, but financial metrics such as revenue decline and increased operating expenses present ongoing challenges.View all SERA earnings summariesSERA Stock 12 Month Forecast
Average Price Target
$5.00
▲(118.34% Upside)
Technical Analysis
Ownership Overview
7.36% Insiders
3.76% Mutual Funds
29.54% Other Institutional Investors
55.94% Public Companies and
Individual Investors